Arrhythmia Research Technology, Inc. Appoints Robert A.

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Arrhythmia Research Technology, Inc. Appoints Robert A. Mello to Board of Directors

FITCHBURG, MA--(Marketwired - Apr 28, 2015) - Arrhythmia Research Technology, Inc. ( NYSE MKT : HRT ) (the "Company") announced today the appointment of Mr. Robert A. Mello to its Board of Directors, effective April 27, 2015. Mr. Mello will serve as a director until his term expires at the 2017 annual meeting of stockholders, at which time he will stand for election by the Company's stockholders.

Mr. Mello brings over 35 years in the medical device, instrumentation and consumables industry to the Board. His experience ranges from startup entrepreneurial companies through the leadership of operations and turn-around situations for both small and large public corporations. He also brings extensive experience in mergers and acquisitions.

Mr. E. P. Marinos, Chairman of the Board, commented, "We are pleased to welcome Bob to the Board. His extensive operational and leadership experience in the medical device industry will help provide diversity of knowledge and capabilities in order to support the management of the Company and the best interests of our shareholders."

Mr. Mello has served as the Vice President and Chief Operating Officer of Advanced Instruments, Inc., a leading global supplier of instrumentation for clinical, pharmaceutical, biotechnology and microbiology laboratories. Prior to that, Mr. Mello served as Corporate Vice President and President of IRIS International, Inc.'s IRIS Sample Processing division. Iris International is a leading provider of automated urinalysis instrumentation and bench top centrifuge products for use in major medical institutions, commercial laboratories, clinics, doctors' offices and research institutions. He spent twelve years with bioMerieux, which designs, manufactures and markets medical instruments and consumables, as both Vice President of Operations at their Boston Immunodiagnostics facility and Vice President of Disposables Manufacturing -- Clinical Microbiology. Prior to joining bioMerieux, Mr. Mello was a founder and Vice President of Operations for Medical & Scientific Designs, Inc., an in-vitro diagnostics company. He spent the earlier years of his career at Ortho Diagnostics, Inc., a division of Johnson & Johnson. Mr. Mello is affiliated with the Diagnostics Marketing Association (DXMA), American Management Association (AMA), American Production and Inventory Control Society (APICS) and is a Certified CPIM. He received his B.S. Management from Lesley University and his Electrical Engineering, ASEE degree from Bristol College.

About Arrhythmia Research Technology, Inc. Arrhythmia Research Technology, Inc., through its wholly-owned subsidiary, Micron Products, Inc., is a diversified contract manufacturing organization that produces highly-engineered, innovative medical device technologies requiring precision machining and injection molding. The Company also manufactures components, devices and equipment for military, law enforcement, industrial and automotive applications. In addition, the Company is a market leader in the production and sale of silver/silver chloride coated and conductive resin sensors used as consumable component parts in the manufacture of integrated disposable electrophysiological sensors. The Company's strategy for growth is to build a best-in-class quality organization and capitalize on its engineering design expertise and reliable, proprietary manufacturing processes to further penetrate the medical device contract manufacturing market.

The Company routinely posts news and other important information on its websites: http://www.arthrt.com and http://www.micronproducts.com .

Safe Harbor Statement Forward-looking statements made herein are based on current expectations of Arrhythmia Research Technology, Inc. ("our" or the "Company") that involve a number of risks and uncertainties and should not be considered as guarantees of future performance. The factors that could cause actual results to differ materially include our ability to retain order volumes from customers who represent significant proportions of net sales; our ability to maintain our pricing model, offset higher costs with price increases and/or decrease our cost of sales; variability of customer delivery requirements; the level of sales of higher margin products and services; our ability to renew our credit facility and manage our level of debt and provisions in the debt agreements which could make the Company sensitive to the effects of economic downturns and limit our ability to react to changes in the economy or our industry; failure to comply with financial and other covenants in our credit facility; volatility in commodity and energy prices and our ability to offset higher costs with price increases; continued availability of supplies or materials used in manufacturing at competitive prices; variability of customer delivery requirements; variations in the mix of products sold; and the amount and timing of investments in capital equipment, sales and marketing, engineering and information technology resources. More information about factors that potentially could affect the Company's financial results is included in the Company's filings with the Securities and Exchange Commission.

Company Contact: Derek T. Welch Chief Financial Officer 978.345.5000

Scroll down for more posts ▼

Top 10 Most Recent News Articles

China Automotive Systems Hits Milestone with ASPICE 4.0 CL2

Updated Category News Views 16

An Automotive Feat in R&D Now here's a story that should make waves across the automotive sector. China Automotive Systems, Inc. (NASDAQ: CAAS), a titan of power steering development in China, has nailed it by meeting the ASPICE 4.0 Capability Level 2. That's a big one, folks. Verified by a partnership between a European automaker and UL, this achievement is no fluke....

Continue Reading
OMLYCLO Shakes Up U.S. Biologic Market as Key Player

Updated Category News Views 16

Ah, the pharmaceutical game is shifting again, and this time Celltrion USA's putting their chips down with OMLYCLO, the shiny new omalizumab biosimilar. Here we see a product that's not just approved but interchangeable with XOLAIR, making it a front-runner in the allergic and inflammatory conditions battleground. If you're a patient or a provider navigating these murky...

Continue Reading
#L.A. Rising Podcast: From Fires to International Fame

Updated Category News Views 18

From Ashes to Airwaves Gritty stories of survival often cut deeper than any wonky industry analysis or corporate earnings report. When you've been through the wringer and come out the other side, that experience sticks with you—and for Kim S. Marshall, it ignited something personal yet universal with the #L.A. Rising podcast. Emerging from the 2025 L.A. fires, this...

Continue Reading
Christmas Injury Lawyers Unveils SC Knowledge Center

Updated Category News Views 6

In the world of legal labyrinths, sometimes you just need a guiding light, especially following a car accident. That's where the freshly launched South Carolina Car Accident Law Knowledge Center steps in. It’s no magic wand, but Christmas Injury Lawyers are certainly trying to cut the chaos. This online hub covers more ground than a small library, boasting 40 guides...

Continue Reading
Travelers Turn to Direct Booking Amid Cost Surge

Updated Category News Views 20

Getting Ahead of the Travel Expense Game Rising fees and tighter budgets haven't persuaded holiday travelers to abandon their plans. Instead, they’re sharpening their axes, looking for clearer paths to their vacation goals without slicing off an arm and a leg. With the cost of travel climbing faster than a runaway elevator, folks are getting smart about where their...

Continue Reading
Dan Brown Joins Guidewire: Big Moves in P&C Software

Updated Category News Views 17

Turning the Insurance World on Its Head Just when you think the enterprise software scene is getting predictable, along comes a bit of news to shake things up. Guidewire, a name known in the P&C insurance software world, has roped in a veteran—Dan Brown—who's got more than a quarter-century under his belt shaping product strategies. It’s not just another suit...

Continue Reading
Event Industry Power 50 Voting Surge Ahead of Close

Updated Category News Views 15

An Unexpected Wave of Enthusiasm in Event Industry The Event Industry Power 50 is getting some serious action this year. Over 3,500 votes have already rolled in, smashing last year's numbers with days still left on the clock. It seems like folks can't wait to see their favorite event powerhouses crowned at this year's gala, which kicks off October 27 in New York City....

Continue Reading
ProClad Unveils Innovative Hybrid 2.0 Cookware

Updated Category News Views 15

Revolutionizing Cookware: The Launch of Hybrid 2.0 Today, everyone's buzzing about ProClad's big reveal—the Hybrid 2.0 Pan. Now, before you roll those skeptical eyes, hear me out. This isn’t your average bit of kitchen fluff; it’s a heavyweight contender stepping into the everyday cooking ring. What they've done here is combine the muscle of stainless steel searing...

Continue Reading
TRIMAX Poised to Meet AI-Driven Power Challenges

Updated Category News Views 13

TRIMAX's Bold Move into AI-Powered Infrastructure It feels like we're standing on the cusp of a seismic shift, folks. Artificial intelligence isn't just another buzzword anymore—it's a juggernaut reshaping our digital world. TRIMAX Power Systems is gearing up to ride this wave, with its eyes set on capturing a chunk of the booming demand for fast-deployable power...

Continue Reading
Palm Beach Royals Boost Pickleball's Popularity Surge

Updated Category News Views 23

A New Era for Pickleball in Palm Beach It might be time to re-evaluate pickleball if you weren't paying attention before. The Palm Beach Royals have wrapped up their first Major League Pickleball season with a bang, marking a pivotal year for the sport. This underdog tale of graft and grit is carving out a new chapter in the world of sport. Record-Breaking Season for MLP...

Continue Reading

Top 5 Most Recently Viewed Articles

Ascletis Kicks Off Phase III Trials for Oral GLP-1 Drug

Updated Category News Views 68

Dose One: A Step Closer to an Oral Obesity Treatment August 30, 2026, marks a pivotal moment for Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") as they announce the first patient dosed in their global phase III clinical trial of ASC30. This little pill might pack a punch, tackling obesity—a beast of a challenge that's battering waistlines globally. So what's the big deal...

Continue Reading
Biodesix and APAPP Team Up for Innovative Lung Cancer Education

Updated Category News Views 128

Collaboration to Enhance Lung Cancer Care Biodesix, Inc. (Nasdaq: BDSX), a prominent name in the diagnostic solutions sector, has announced an exciting new partnership with the Association of Pulmonary Advanced Practice Providers (APAPP). This collaboration aims to roll out comprehensive educational programs designed specifically for Advanced Practice Providers (APPs),...

Continue Reading
Westinghouse's New Contract Propels AP1000 Reactor Feasibility

Updated Category News Views 219

Westinghouse's Strategic Contract with GEN energija Westinghouse Electric Company announced an exciting partnership with Slovenia’s state-owned power firm GEN energija. The duo aims to conduct a comprehensive Technical Feasibility Study (TFS) focused on the deployment of the AP1000 reactor, a pivotal part of Slovenia's nuclear new-build strategy. Collaborating alongside...

Continue Reading
AbbVie Enhances Psychiatry Pipeline with Gilgamesh Acquisition

Updated Category News Views 199

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin AbbVie (NYSE: ABBV) has successfully finalized its acquisition of Gilgamesh Pharmaceuticals' lead investigational compound, bretisilocin. This strategic acquisition strengthens AbbVie's commitment to pioneering innovations in psychiatric treatments. Expanding the Psychiatry Pipeline The acquisition of...

Continue Reading
Automotive Wiring Harness Market Poised for Growth

Updated Category News Views 8

Market Projections and Growth Trajectory Roll up your sleeves, folks, because the automotive wiring harness market is gearing up for some shifts. Aiming to expand from $42.95 billion in 2026 to a robust $49.29 billion by 2033, the projected CAGR clocks in at a humble 2%, but don’t be fooled—there’s more beneath the surface here that’s worth a seasoned glance. BEV...

Continue Reading